RS64987B1 - Monoklonsko antitelo koje antagonizuje i inhibira vezivanje humanog pd-1 antigena za njegov ligand, metoda njegovog pripremanja i njegova primena - Google Patents
Monoklonsko antitelo koje antagonizuje i inhibira vezivanje humanog pd-1 antigena za njegov ligand, metoda njegovog pripremanja i njegova primenaInfo
- Publication number
- RS64987B1 RS64987B1 RS20231241A RSP20231241A RS64987B1 RS 64987 B1 RS64987 B1 RS 64987B1 RS 20231241 A RS20231241 A RS 20231241A RS P20231241 A RSP20231241 A RS P20231241A RS 64987 B1 RS64987 B1 RS 64987B1
- Authority
- RS
- Serbia
- Prior art keywords
- antigen
- ligand
- human
- preparation
- application
- Prior art date
Links
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710262053.4A CN106939049B (zh) | 2017-04-20 | 2017-04-20 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
PCT/CN2017/089282 WO2018192089A1 (zh) | 2017-04-20 | 2017-06-21 | 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用 |
EP17906230.2A EP3613768B1 (en) | 2017-04-20 | 2017-06-21 | Monoclonal antibody antagonizing and inhibiting binding between human pd-1 antigen and ligand thereof, preparation method therefor and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
RS64987B1 true RS64987B1 (sr) | 2024-01-31 |
Family
ID=59464668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20231241A RS64987B1 (sr) | 2017-04-20 | 2017-06-21 | Monoklonsko antitelo koje antagonizuje i inhibira vezivanje humanog pd-1 antigena za njegov ligand, metoda njegovog pripremanja i njegova primena |
Country Status (9)
Country | Link |
---|---|
US (1) | US11345754B2 (sr) |
EP (1) | EP3613768B1 (sr) |
JP (1) | JP6928971B2 (sr) |
CN (1) | CN106939049B (sr) |
ES (1) | ES2969235T3 (sr) |
HR (1) | HRP20240102T1 (sr) |
PL (1) | PL3613768T3 (sr) |
RS (1) | RS64987B1 (sr) |
WO (1) | WO2018192089A1 (sr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
CN108299561B (zh) * | 2018-01-02 | 2020-11-13 | 暨南大学 | 一种pd-1纳米抗体及其克隆表达方法与应用 |
CN108997497B (zh) | 2018-03-30 | 2022-02-25 | 华兰基因工程有限公司 | 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用 |
CN110878122B (zh) * | 2018-09-06 | 2023-07-28 | 上海张江生物技术有限公司 | 重组抗pd-l1单克隆抗体 |
CN109053892B (zh) | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
WO2020123375A1 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Pdcd-1 homing endonuclease variants |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
WO2021088904A1 (zh) * | 2019-11-08 | 2021-05-14 | 先声生物医药科技有限公司 | 抗人程序性死亡配体-1(pd-l1)的抗体及其用途 |
CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
RU2406760C3 (ru) * | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
SI2170959T1 (sl) * | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CN104479018B (zh) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
RU2625034C2 (ru) * | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
US9815897B2 (en) * | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
CN103242448B (zh) | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
CN104560884A (zh) * | 2013-10-25 | 2015-04-29 | 苏州思坦维生物技术有限责任公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途 |
CA2932966C (en) | 2013-12-12 | 2022-03-22 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2016008067A1 (zh) | 2014-07-14 | 2016-01-21 | 惠州市吉瑞科技有限公司 | 一种吸烟控制方法、吸烟控制电路以及电子烟 |
ES2847311T3 (es) * | 2014-08-05 | 2021-08-02 | MabQuest SA | Reactivos inmunológicos que se unen a PD-1 |
DK3237446T3 (en) * | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
EP3334763A4 (en) * | 2015-08-11 | 2019-04-03 | Wuxi Biologics (Cayman) Inc. | NOVEL ANTI-PD-1 ANTIBODIES |
RS63490B1 (sr) * | 2015-10-02 | 2022-09-30 | Symphogen As | Anti-pd-1 antitela i kompozicije |
-
2017
- 2017-04-20 CN CN201710262053.4A patent/CN106939049B/zh active Active
- 2017-06-21 PL PL17906230.2T patent/PL3613768T3/pl unknown
- 2017-06-21 US US16/606,779 patent/US11345754B2/en active Active
- 2017-06-21 ES ES17906230T patent/ES2969235T3/es active Active
- 2017-06-21 JP JP2019556961A patent/JP6928971B2/ja active Active
- 2017-06-21 EP EP17906230.2A patent/EP3613768B1/en active Active
- 2017-06-21 WO PCT/CN2017/089282 patent/WO2018192089A1/zh active Application Filing
- 2017-06-21 RS RS20231241A patent/RS64987B1/sr unknown
- 2017-06-21 HR HRP20240102TT patent/HRP20240102T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3613768C0 (en) | 2023-11-22 |
EP3613768B1 (en) | 2023-11-22 |
ES2969235T3 (es) | 2024-05-17 |
JP6928971B2 (ja) | 2021-09-01 |
PL3613768T3 (pl) | 2024-05-06 |
WO2018192089A1 (zh) | 2018-10-25 |
EP3613768A1 (en) | 2020-02-26 |
US11345754B2 (en) | 2022-05-31 |
CN106939049A (zh) | 2017-07-11 |
CN106939049B (zh) | 2019-10-01 |
EP3613768A4 (en) | 2020-06-17 |
HRP20240102T1 (hr) | 2024-03-29 |
US20200277376A1 (en) | 2020-09-03 |
JP2020517264A (ja) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3613768C0 (en) | MONOCLONAL ANTIBODY ANTAGONIST AND INHIBITOR OF THE BINDING BETWEEN HUMAN PD-1 ANTIGEN AND ITS LIGAND, ASSOCIATED PREPARATION METHOD AND CORRESPONDING APPLICATION | |
EP3575322A4 (en) | ANTI-PD-1 MONOCLONAL ANTIBODY, PROCESS OF PREPARATION AND APPLICATION | |
HK1257518A1 (zh) | 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 | |
EP3470427A4 (en) | MONOCLONAL INTERLEUKIN-17A HUMAN ANTIBODIES, PREPARATION METHOD AND USE THEREOF | |
ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
EP3176182A4 (en) | Anti-pd-1 monoclonal antibody and obtaining method therefor | |
EP3878869A4 (en) | NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE | |
EP3882276A4 (en) | BISPECIFIC ANTIBODY, METHOD OF PRODUCTION THEREOF AND USE THEREOF | |
EP3967713A4 (en) | BISPECIFIC ANTIBODY, METHOD FOR PREPARATION AND APPLICATION | |
EP3851455A4 (en) | MONOCLONAL ANTIBODIES SPECIFICALLY BINDING TO HUMAN AND MONKEY ANTIGEN CD38, PROCESS FOR PREPARATION AND USE | |
SG11202011201QA (en) | Fully human antibodies against ox40, method for preparing same, and use thereof | |
EP3822290A4 (en) | SEMA4D ANTIBODY, METHOD FOR ITS PRODUCTION AND ITS USE | |
EP3321284A4 (en) | Monoclonal antibody of human procalcitonin, preparation method therefor, and application thereof | |
IL291545A (en) | Antibodies against ctla4, antibody fragments, their immunoconjugates and their uses | |
IL274121A (en) | Bispecific antibodies that bind ALK-1 and BMPR-2 | |
EP3981793A4 (en) | CEACAM5-RESISTANT MONOCLONAL ANTIBODY AND METHODS FOR ITS PRODUCTION AND ITS USE | |
EP3730518A4 (en) | MONOCLONAL ANTIBODY BINDING TO HUMAN IL-5, METHOD FOR PREPARATION AND USE | |
ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
IL277969A (en) | Antibodies that bind 1-PD and uses thereof | |
EP3242895A4 (en) | A novel anti-egfr monoclonal antibody, method of making, and use thereof | |
IL272733A (en) | Monoclonal antibodies against pathological alpha-synuclein, and methods using same | |
EP3722311A4 (en) | HUMAN ANTI-IL6 MONOCLONAL ANTIBODIES, METHOD FOR THE PREPARATION AND USE THEREOF | |
EP3375875A4 (en) | SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME | |
EP3608335A4 (en) | HUMANIZED ANTI-TPBG ANTIBODY, PRODUCTION METHOD THEREFOR, CONJUGATE THEREOF AND APPLICATIONS | |
EP3758751A4 (en) | MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF |